Yasser Diab1, Mustafa Zelal Muallem2. 1. Department of Gynecology, Portland District Hospital, Victoria, Australia. 2. Department of Gynecology with Center for Oncological Surgery, Campus Virchow-Klinikum, Charité Medical University, Berlin, Germany Mustafa-Zelal.Muallem@charite.de.
Abstract
BACKGROUND/AIM: We aimed to identify the most effectual groups of targeted therapies for ovarian cancer in recent clinical trials. MATERIALS AND METHODS: A systematic literature review has been gathered on an inventive study design that comprises of five steps. This involves search for pertinent publications from 2010 to date in various accessible medical data bases, usage of inclusion and exclusion, appraisal of quality of the studies included, abstraction of the relevant data and intelligible amalgamation of the data abridged in an evocative and narrative style. RESULTS: Three types of modalities of targeted-therapy drugs have been identified; angiogenesis inhibition, signal enzymes inhibition and apoptosis induction in the tumor cells. CONCLUSION: There has been a surge in clinical trials with drugs that specifically target signal enzymes, induce apoptosis and inhibit angiogenesis in site-specific ovarian cancer cells, which could be very promising to design a more efficacious protocol for treating the disease. Copyright
BACKGROUND/AIM: We aimed to identify the most effectual groups of targeted therapies for ovarian cancer in recent clinical trials. MATERIALS AND METHODS: A systematic literature review has been gathered on an inventive study design that comprises of five steps. This involves search for pertinent publications from 2010 to date in various accessible medical data bases, usage of inclusion and exclusion, appraisal of quality of the studies included, abstraction of the relevant data and intelligible amalgamation of the data abridged in an evocative and narrative style. RESULTS: Three types of modalities of targeted-therapy drugs have been identified; angiogenesis inhibition, signal enzymes inhibition and apoptosis induction in the tumor cells. CONCLUSION: There has been a surge in clinical trials with drugs that specifically target signal enzymes, induce apoptosis and inhibit angiogenesis in site-specific ovarian cancer cells, which could be very promising to design a more efficacious protocol for treating the disease. Copyright